Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03126630 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
A Phase 1 study of Pleural Malignant Mesothelioma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 20
- Study locations
NCT03126630 is a Phase 1 study of Pleural Malignant Mesothelioma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 49 participants, below the 55-participant average among 4 other Pleural Malignant Mesothelioma trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT03126630, a Phase 1 study of Pleural Malignant Mesothelioma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I/II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine works in treating patients with mesothelin-positive pleural mesothelioma. Anetumab ravtansine is a monoclonal antibody, called anetumab, linked to a chemotherapy drug, called ravtansine. Anetumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as mesothelin receptors, and delivers ravtansine to kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and anetumab ravtansine may work better in treating patients with mesothelin-positive pleural mesothelioma.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- BIOLOGICAL Anetumab Ravtansine
Study Locations (20)
Florida
- UM Sylvester Comprehensive Cancer Center at Aventura - Aventura
- UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
- Mayo Clinic in Florida - Jacksonville
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
- UM Sylvester Comprehensive Cancer Center at Kendall - Miami
- UM Sylvester Comprehensive Cancer Center at Plantation - Plantation
California
- City of Hope Comprehensive Cancer Center - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- USC Norris Oncology/Hematology-Newport Beach - Newport Beach
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Illinois
- Northwestern University - Chicago
- University of Chicago Comprehensive Cancer Center - Chicago
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Colorado
- UCHealth University of Colorado Hospital - Aurora
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2027-02-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03126630
The ClinicalTrials.gov registry entry for NCT03126630 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55-participant average among 4 other Pleural Malignant Mesothelioma trials with a reported enrollment target (11% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pleural Malignant Mesothelioma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03126630 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03126630 about?
NCT03126630 is a clinical study titled "Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma". This phase I/II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine works in treating patients with mesothelin-positive pleural mesothelioma. Anetumab ravtansine is a monoclonal antibody, called anetumab, linked to a chemotherapy drug, called ravtansine. Ane...
What is the current status of trial NCT03126630?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-10-04. Estimated completion is 2027-02-18.
What conditions does trial NCT03126630 study?
This clinical trial studies the following conditions: Pleural Malignant Mesothelioma.
What interventions are being tested in trial NCT03126630?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Anetumab Ravtansine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03126630?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03126630 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pleural Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab in Treating Patients With Malignant Mesothelioma
ACTIVE NOT RECRUITING · Phase 2
-
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.